Target Information

Target General Infomation
Target ID
T71377
Former ID
TTDR00012
Target Name
Interleukin 3 receptor
Gene Name
IL3RA
Synonyms
CD123 antigen; IL-3R-alpha; IL3RA
Target Type
Clinical Trial
Disease Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9:204.0, 556; ICD10: C91.0, C92.0]
Leukemia [ICD9: 208.9; ICD10: C90-C95]
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890]
Function
This is a receptor for interleukin-3.
BioChemical Class
Cytokine receptor
UniProt ID
P26951
Sequence
MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM
PAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL
SCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS
HILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL
QIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN
TRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG
KAGLEECLVTEVQVVQKT
Drugs and Mode of Action
Drug(s) CSL-362-AML Drug Info Phase 1 Leukemia [549073]
MGD006 Drug Info Phase 1 Acute lymphoblastic leukemia; Acute myeloid lymphoma [544458], [889399]
Daniplestim Drug Info Terminated Osteoporosis [546034]
Agonist Daniplestim Drug Info [535051]
Modulator MGD006 Drug Info [544458]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Apoptosis
Jak-STAT signaling pathway
Hematopoietic cell lineage
NetPath Pathway IL5 Signaling Pathway
IL3 Signaling Pathway
Pathway Interaction Database IL3-mediated signaling events
Reactome GPVI-mediated activation cascade
gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways IL-3 Signaling Pathway
Interleukin-2 signaling
Interleukin-3, 5 and GM-CSF signaling
References
Ref 544458A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
Ref 546034Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005988)
Ref 549073Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031973)
Ref 889399ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Ref 532602Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.
Ref 535051The combined administration of daniplestim and Mpl ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. Stem Cells. 1998;16 Suppl 2:143-54.
Ref 544458A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.